Publications by authors named "Y Miyasaka"

Background/aim: Liver metastasis (LM), pre-dominant in pancreatic cancer, is associated with a dismal 5-year survival rate. Reports on the presence of fatty liver and liver fibrosis in LM are conflicting. Although liver biopsy is the standard diagnostic method for fibrosis, alternative, less invasive scoring models have been explored.

View Article and Find Full Text PDF

Streptozotocin (STZ) is widely used as a pancreatic beta-cell toxin to induce experimental diabetes in rodents. Strain-dependent variations in STZ-induced diabetes susceptibility have been reported in mice. Differences in STZ-induced diabetes susceptibility are putatively related to pancreatic beta-cell fragility via DNA damage response.

View Article and Find Full Text PDF

An unconventional myosin, myosin VI gene (MYO6), contributes to recessive and dominant hearing loss in humans and mice. The Kumamoto shaker/waltzer (ksv) mouse is a model of deafness resulting from a splice-site mutation in Myo6. While ksv/ksv homozygous mice are deaf due to cochlear hair cell stereocilia fusion at the neonatal stage, the hearing phenotypes of ksv/+ heterozygous mice have been less clear.

View Article and Find Full Text PDF

Background: The potential of carbon ion radiation therapy (CIRT) as a curative treatment for localized prostate cancer (PCa) has garnered attention due to its characteristic dose distribution. We prospectively collected and analyzed over five years to investigate the outcomes of localized PCa treated with CIRT at our institution.

Patients And Methods: The study included patients with histologically confirmed prostate adenocarcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore if blocking the CCR2 receptor could prevent pulmonary arterial hypertension (PAH) in rat models and improve inflammatory and vascular issues.
  • Researchers used genetically modified Ccr2(-/-) rats and found that these rats showed lower blood pressure in the heart, reduced inflammation, and less vascular damage after being exposed to certain treatments that typically induce PAH.
  • Additionally, combining the CCR2 blockade with the PDE5 inhibitor tadalafil further improved symptoms of pulmonary hypertension, suggesting a potential therapeutic approach for PAH.
View Article and Find Full Text PDF